Pain evaluation in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the PARABO observation study

被引：0
|
作者：
Palmedo, H. [1 ]
Eschmann, S. [2 ]
Werner, A. [3 ]
Selinski, I. [4 ]
Moellers, M-O. [5 ]
Kalinovsky, J. [6 ]
Benson, A. [7 ]
Poeppel, T. [8 ]
机构：
[1] Johanniter Hosp, Canc Ctr, Dept Nucl Med, Bonn, Germany
[2] Marien Hosp, Nucl Med, Stuttgart, Germany
[3] Radiol Schwetzingen, Radiol, Schwetzingen, Germany
[4] Goethe Univ Hosp Frankfurt, Ctr Radol, Frankfurt, Germany
[5] Klinikum Westfalen, Nucl Med, Dortmund, Germany
[6] Bayer Consumer Care Switzerland, Global Med Affairs, Basel, Switzerland
[7] Bayer HealthCare Pharmaceut, Stat, Whippany, NJ USA
[8] Univ Hosp Essen, Nucl Med, Essen, Germany
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
860P
引用
收藏
页码：336 / 336
页数：1
相关论文
共 50 条
  • [21] Clinical outcomes of patients with metastatic castration-resistant prostate cancer (mCRPC) receiving radium-223 (Ra-223) early versus late in the treatment sequence.
    Mbuagbaw, Lawrence
    Lowther, Jennifer
    Lee-Ying, Richard M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [22] A randomized phase 2 study investigating 3 dosing regimens of radium-223 dichloride (Ra-223) in bone metastatic castration-resistant prostate cancer (mCRPC).
    Sternberg, Cora N.
    Saad, Fred
    Graff, Julie Nicole
    Peer, Avivit
    Vaishampayan, Ulka N.
    Leung, Eugene
    Rosenbaum, Eli
    Gurney, Howard
    Epstein, Richard
    Davis, Ian D.
    Wu, Bingyan
    Trandafir, Lucia
    Wagner, Volker Jean
    Hussain, Maha
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [23] UTILIZATION OF RADIUM-223 DICHLORIDE (RA-223) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN CANADA: A REAL-WORLD RETROSPECTIVE STUDY
    Lapierre, M.
    Fraelic, A.
    VALUE IN HEALTH, 2016, 19 (03) : A162 - A162
  • [24] Serum biomarkers of bone metabolism in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with radium-223 (Ra223): Results from a prospective multicentre study
    Romero Laorden, N.
    Lozano Mejorada, R.
    Hernandez Jorge, A.
    Lainez, N.
    Almagro Casado, E.
    Fernandez Calvo, O.
    Hernando, S.
    Fernandez Freire, A.
    Gonzalez Billalabeitia, E.
    Chirivella, I.
    Garcia Dominguez, R.
    Anido Herranz, U.
    Vazquez Mazon, F. J.
    Ros, S.
    Montesa, A.
    De Velasco Oria de Rueda, G. A.
    Morales Barrera, R.
    Lorente, D.
    Castro, E.
    Olmos Hidalgo, D.
    ANNALS OF ONCOLOGY, 2019, 30 : 344 - 344
  • [25] Contemporary use of radium-223 (Ra-223) in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Feasibility and safety.
    Emamekhoo, Hamid
    Chowdry, Rajasree Pia
    Elson, Paul
    Ledet, Elisa M.
    Martin, Allison
    Cotogno, Patrick
    Beach, Jennifer
    Steinberger, Allie E.
    Allman, Kimberly D.
    Stolten, Michael
    Garcia, Jorge A.
    Sartor, Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [26] FDG PET/CT as a tool to provide the prognostic stratification and response assessment of metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride (Ra-223)
    Bauckneht, M.
    Capitanio, S.
    Fornarini, G.
    Ceriani, V.
    Ippoliti, M.
    Ciarmiello, A.
    Giovacchini, G.
    Bongioanni, F.
    Piccardo, E.
    Agnese, G.
    Di Ciolo, L.
    Sambuceti, G.
    Morbelli, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S527 - S528
  • [27] Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) sequentially treated with abiraterone acetate (AA) and radium-223 (RA223).
    Caffo, Orazio
    Frantellizzi, Viviana
    Tucci, Marcello
    Galli, Luca
    Monari, Fabio
    Baldari, Sergio
    Masini, Cristina
    Bortolus, Roberto
    Facchini, Gaetano
    Alongi, Pierpaolo
    Zichi, Clizia
    Biasco, Elisa
    Fanti, Stefano
    Pignata, Salvatore
    Filice, Angelina
    Borsatti, Eugenio
    Rossetti, Sabrina
    Spada, Massimiliano
    Cortesi, Enrico
    De Vincentis, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [28] Pain response in a population-based study of radium-223 (Ra223) for metastatic castration-resistant prostate cancer
    Parimi, Sunil
    Bondy, Suraya
    Tsang, Erica
    McKenzie, Michael Ross
    Bachand, Francois
    Aparicio, Maria
    Duncan, Graeme
    Sunderland, Katherine
    Olson, Robert Anton
    Pai, Howard Huaihan
    Alexander, Abraham Skaria
    LaPointe, Vincent
    Chi, Kim N.
    Tyldesley, Scott
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2019, 13 (10): : E311 - E316
  • [29] Alkaline phosphatase (ALP) decline and pain response as markers for overall survival (OS) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (223Ra) in the REASSURE study
    O'Sullivan, J.
    Heinrich, D.
    Marcos, E. Castro
    George, S.
    Song, D. Y.
    Dizdarevic, S.
    Baldari, S.
    Essler, M.
    de Jong, I. J.
    Lastoria, S.
    Hammerer, P. G.
    Tombal, B.
    James, N. D.
    Verholen, F.
    Meltzer, J.
    Sandstroem, P.
    Sartor, O.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1181 - S1181
  • [30] Real-world utilization of radium-223 (Ra-223) for the treatment of metastatic castration-resistant prostate cancer (mCRPC): A US tertiary oncology center analysis
    McKay, Rana R.
    Silver, Rebecca
    Bhak, Rachel
    Korves, Caroline
    Cheng, Mu
    Appukkuttan, Sreevalsa
    Simmons, Stacey J.
    Duh, Mei Sheng
    Taplin, Mary-Ellen
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
12345